WallStreetZenWallStreetZen

NASDAQ: PHAR
Pharming Group Nv Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

PHAR past revenue growth

How has PHAR's revenue growth performed historically?
Company
24.61%
Industry
148.64%
Market
17.33%
PHAR's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
PHAR's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
PHAR's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

PHAR earnings and revenue history

Current Revenue
$272.6M
Current Earnings
-$11.7M
Current Profit Margin
-4.3%

PHAR Return on Equity

Current Company
-5.1%
Current Industry
-63.5%
Current Market
188%
PHAR's Return on Equity (-5.1%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when PHAR announces earnings.

PHAR Return on Assets

Current Company
-2.4%
Current Industry
2.9%
PHAR is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

PHAR Return on Capital Employed

Current Company
-3.12%
Current Industry
19.5%
PHAR's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

PHAR vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
PHAR$266.65M$4.25M-$11.47M+11.91%N/A
CABA$0.00-$64.18M-$67.68MN/AN/A
PRAX$2.45M-$122.01M-$123.28MN/AN/A
AVTE$0.00-$75.37M-$75.52MN/AN/A
SVRA$0.00-$50.09M-$54.70M-100.00%N/A
View Top Biotech Stocks

PHAR earnings dates

Next earnings date
May 8, 2024

Pharming Group Nv Earnings & Revenue FAQ

What were PHAR's earnings last quarter?

On Invalid Date, Pharming Group Nv (NASDAQ: PHAR) reported Q4 2023 earnings per share (EPS) of -$0.06, up 76.07% year over year. Total Pharming Group Nv earnings for the quarter were -$3.47 million. In the same quarter last year, Pharming Group Nv's earnings per share (EPS) was -$0.23.

If you're new to stock investing, here's how to buy Pharming Group Nv stock.

What was PHAR's earnings growth in the past year?

As of Q2 2024, Pharming Group Nv's earnings has grown year over year. Pharming Group Nv's earnings in the past year totalled -$11.47 million.

What is PHAR's earnings date?

Pharming Group Nv's earnings date is Invalid Date. Add PHAR to your watchlist to be reminded of PHAR's next earnings announcement.

What was PHAR's revenue last quarter?

On Invalid Date, Pharming Group Nv (NASDAQ: PHAR) reported Q4 2023 revenue of $90.24 million up 55.3% year over year. In the same quarter last year, Pharming Group Nv's revenue was $58.11 million.

What was PHAR's revenue growth in the past year?

As of Q2 2024, Pharming Group Nv's revenue has grown 24.61% year over year. This is 124.03 percentage points lower than the US Biotechnology industry revenue growth rate of 148.64%. Pharming Group Nv's revenue in the past year totalled $266.65 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.